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The comparison of clinical outcomes  
of endophthalmitis from fluoroquinolone- 
resistant and susceptible bacteria
Purpose: To identify patients who developed acute-onset endophthalmitis after clear corneal 
cataract surgery, and to compare treatment outcomes between cases caused by fluoroquinolone 
susceptible organisms versus fluoroquinolone resistant organisms.
Design: Retrospective case series.
Methods: Patients who developed endophthalmitis within six weeks of cataract surgery, and 
were treated between January 1996 and December 2008 at Bascom Palmer Eye Institute in 
Miami, Florida, were identified retrospectively. Clinical features, organisms cultured, and visual 
acuity outcomes were evaluated.
Results: A total of 97 patients met study criteria, and 37 (38%) demonstrated in vitro fluoroqui-
nolone resistance. All fluoroquinolone resistant endophthalmitis in the study was caused by either 
Staphylococcus epidermidis (n = 32) or Staphylococcus aureus (n = 5). Presenting clinical features 
were similar between fluoroquinolone resistant and fluoroquinolone susceptible groups. Final 
visual acuity was 20/40 in 49% of fluoroquinolone-resistant cases and 42% of fluoroquinolone-
susceptible cases.  All fluoroquinolone-resistant isolates were susceptible to vancomycin.
Conclusion: In the current study, approximately one-third of isolates were resistant to fluo-
roquinolones. There was no significant difference in clinical outcomes in this study, regardless 
of fluoroquinolone susceptibility.
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Introduction
Endophthalmitis is a serious but uncommon complication following cataract surgery. 
The incidence of endophthalmitis after cataract surgery is reported to be between 0.05% 
and 0.68%.1–5 Topical fluoroquinolone (FQ) antibiotics are commonly used for prophy-
laxis, during the perioperative period for cataract surgery. Prophylactic use of topical FQs 
may theoretically reduce the rate of endophthalmitis by lowering the bacterial load on the 
ocular surface.6–8 However, the actual effectiveness of using FQs to prevent acute-onset 
endophthalmitis after cataract surgery remains controversial, particularly since endo-
phthalmitis may still occur after the use of antibiotic prophylaxis.9 Although prophylactic 
antibiotic use is often left to the discretion of the cataract surgeon, preoperative use of 
povidone-iodine has become the standard of care.10–12 This 12-year study reports on 
treatment outcomes in acute-onset endophthalmitis after clear corneal cataract surgery 
and compares outcomes between FQ-resistant and FQ-susceptible organisms.
Methods
Microbiology records were used to identify all cases of culture-positive endophthalmitis 
at Bascom Palmer Eye Institute in Miami, Florida from January 1996 to December 
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2008. Clinical records were retrospectively accessed of these 
identified cases, and all patients with endophthalmitis within 
six weeks of clear corneal cataract surgery were included in 
the study. The study included patients who underwent surgery 
at an outside institution and were referred for care as well as 
patients who underwent surgery at Bascom Palmer Eye Insti-
tute. Patients excluded were those who underwent nonclear 
corneal cataract surgery, had combined ophthalmic surgical 
procedures, and patients who developed endophthalmitis 
greater than six weeks after cataract surgery. All patients 
received initial treatment with intravitreal antibiotics. A vit-
reous specimen was also taken at diagnosis. The decision to 
perform a vitrectomy was made by the treating ophthalmic 
physician, generally in accordance with the evidence from the 
Endophthalmitis Vitrectomy Study.3 Recorded data included 
clinical features, visual acuity at diagnosis, cultured organ-
isms and antibiotic susceptibilities, and visual acuity at fol-
lowup. FQ resistance in an organism was defined by the lack 
of susceptibility to ciprofloxacin, levofloxacin, moxifloxacin, 
or gatifloxacin.
Results
In the 12-year time period, 97 patients met study criteria. 
Of these 97 patients, 37 (38%) had endophthalmitis caused 
by FQ-resistant organisms and 60 (62%) had endophthal-
mitis caused by FQ-susceptible organisms. These groups 
had similar presenting clinical features (Table 1). Of the   
FQ-resistant group, 35/37 (95%) had a presenting visual 
acuity of 5/200, whereas 48/60 (80%) had a presenting 
visual acuity of 5/200 in the FQ-susceptible group. Hypo-
pyon was present in 32/37 (86%) and 50/60 (83%) of the   
FQ-resistant and -susceptible groups, respectively. On average, 
the diagnosis of endophthalmitis was made at postoperative 
day 12 after cataract surgery in the FQ-resistant group and 
at postoperative day 13 in the FQ-susceptible group.
Visual acuities at final followup were similar between the 
FQ-resistant and -susceptible groups (Table 2). Final visual 
acuity 20/100 was achieved in 27/37 (73%) of patients 
in the FQ-resistant group, and 36/60 (60%) of patients in 
the FQ-susceptible group. Final visual acuity of no light 
perception (NLP) was noted in 2/37 (5%) and 4/60 (7%) 
of patients in the FQ-resistant and FQ-susceptible groups, 
respectively.
The endophthalmitis cases were also classified by caus-
ative organism in both the FQ-susceptible and FQ-resistant 
groups (Tables 3 and 4). Of the 60 FQ-susceptible cases, 27 
(45%) were caused by Staphylcoccus epidermidis, four were 
caused by S. aureus (7%), and 29 (48%) were caused by other 
organisms, including Streptococcus and Gram-negative spe-
cies. Amongst the FQ-susceptible S. epidermidis, 23/27 (85%) 
had a final visual acuity of 20/100 and no patients had 
a final visual acuity of NLP. Of the FQ-susceptible 
S. aureus, 1/4 (25%) had a final visual acuity of 20/100 and 
also no patients had a final visual acuity of NLP. Regarding the 
other causative organisms in the FQ-susceptible group, 12/29 
(41%) had a final visual acuity of 20/100 and 4/29 (14%) 
had a final visual acuity of NLP.
Of the 37 FQ-resistant cases, 32 (86%) were caused by 
S. epidermidis, and five (14%) were caused by S. aureus. 
Amongst the FQ-resistant S. epidermidis, 25/32 (78%) had 
a final visual acuity of 20/100 and no patients had a final 
visual acuity of NLP. In the FQ-resistant S. aureus group, 
2/5 (40%) patients had a final visual acuity of 20/100   
and 2/5 (40%) patients had a final visual acuity of NLP. 
Of the FQ-resistant S. aureus group, 3/5 (60%) were also 
methicillin-resistant; two of these patients had a final visual 
acuity of NLP, and the remaining one had a final visual acu-
ity of 20/100. The two patients in the FQ-resistant S. aureus 
group with methicillin-susceptible organisms had final visual 
acuities of 20/40 and HM.
Table 1 Presenting clinical characteristics of patients with 
  endophthalmitis following clear corneal cataract surgery
Total n = 97 VA 5/200 Hypopyon Days to diagnosis
FQ resistant
(n = 37)
35
(95%)
32
(86%)
12
FQ susceptible
(n = 60)
48
(80%)
50
(83%)
13
Table 2 Final visual acuities by fluoroquinolone susceptibility
Total n = 97 20/40 20/100 5/200 NLP
FQ resistant
(n = 37)
18
(49%)
27
(73%)
9
(24%)
2
(5%)
FQ susceptible
(n = 60)
25
(42%)
36
(60%)
15
(25%)
4
(7%)
Table 3 Final visual acuities by cultured organism in fluoroquinolone 
susceptible cases
Total n = 60 20/40 20/100 5/200 NLP
S. epidermidis
(n = 27)
17
(63%)
23
(85%)
1
(4%)
0
S. aureus  
(n = 4)
1
(25%)
1
(25%)
3
(75%)
0
Othera
(n = 29)
7
(24%)
12
(41%)
11
(38%)
4
(14%)
aOther cultured organisms included Streptococcus and gram-negative species.Clinical Ophthalmology 2010:4 213
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Organisms resistant to FQs were 100% susceptible 
to vancomycin. These FQ-resistant organisms were also 
noted to be 66% susceptible to gentamicin, trimethoprim/
sulfamethoxazole, and clindamycin.
Discussion
Endophthalmitis can be a devastating complication after 
cataract surgery. In an attempt to reduce the rates of this 
complication, topical fluoroquinolones are commonly used 
as prophylaxis in the perioperative period of cataract surgery 
at the discretion of the operating surgeon. The topical use of 
FQs theoretically decreases the viable organisms that enter 
the eye intraoperatively. FQs may achieve high intraocular 
concentrations via corneal penetration of the drug, but 
their prophylactic use is controversial.11 Some studies have 
suggested that use of topical perioperative FQs does not 
decrease the incidence of culture-positive endophthalmitis 
after cataract surgery.9,13 The use of intracameral antibiot-
ics has also been recommended as an effective method of 
prophylaxis.14–16 The European Society of Cataract and 
Refractive Surgeons (ESCRS) Endophthalmitis Study Group 
reported a 4.92-fold increase in the risk for total postoperative 
endophthalmitis in their study of 16,603 patients, 82% of 
which underwent clear corneal cataract surgery.17 A total of 
29 patients (0.17%) presented with endophthalmitis in that 
study, which is higher than the 0.03% incidence previously 
reported at our institution.1,17
The findings of the current study were comparable to 
those of the ESCRS study and the Endophthalmitis Vitrec-
tomy Study (EVS) for cases of culture-proven, acute-onset 
endophthalmitis (Table 5). The organisms cultured and the 
percentage of patients with a final visual acuity of 20/40 
was similar among the three studies.18,19
Also of note, the treatment protocol in the EVS included 
intravitreal injections of vancomycin and amikacin and 
subconjunctival injections of vancomycin, ceftazidime, 
and dexamethasone.3 In the current study, all of the patients 
with endophthalmitis received treatment consisting of only 
intravitreal injections of vancomycin, ceftazidime, and dexa-
methasone. As previously reported, no difference was noted 
in clinical outcomes after acute-onset endophthalmitis using 
the latter intravitreal regimen.1
Limitations to this study include its retrospective nature; 
since most of the study patients were referred from outside 
institutions, data on prophylactic preoperative or postopera-
tive use of antibiotics were not available. Additionally, data 
related to preoperative vision and potential intraoperative 
surgical complications were unavailable. Another limitation 
is that it remains unclear whether the endophthalmitis in   
FQ-resistant cases was caused by initially FQ-resistant 
  organisms or if the FQ resistance was developed by an ini-
tially FQ-susceptible organism during the course of the 
infection. FQs remain an important antibiotic, but cover-
age of Staphylococcus species remains inconsistent.20 All 
FQ-resistant organisms in this study were susceptible to 
vancomycin, and a significant proportion of the organ-
isms were also susceptible to tetracyclines, gentamicin, 
trimethoprim/sulfamethoxazole, and clindamycin.
In the current study, approximately one-third of isolates 
cultured from acute-onset endophthalmitis after cataract 
surgery were resistant to FQs. Both the FQ-resistant and   
FQ-susceptible groups had similar presenting clinical features, 
and the decision for immediate vitrectomy versus intravitreal 
tap and inject was made with the suggestions of the EVS.3 
No significant difference in clinical outcomes was noted, 
regardless of FQ susceptibility.
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Table 4 Final visual acuities by cultured organism in fluoroquinolone 
resistant cases
Total n = 37 20/40 20/100 5/200 NLP
S. epidermidis
(n = 32)
17
(53%)
25
(78%)
4
(13%)
0
S. aureus
(n = 5)
1
(20%)
2
(40%)
1
(20%)
2
(40%)
Table 5 Organisms and clinical features of culture-proven, acute-
onset endophthalmitis: comparison of EVS, ESCRS, and current 
studies3,14,17–19
EVS ESCRS Current study
Number of patients 291 19 97
% coagulase (-)  
Staphylococcusa
70% 42% 62%
% S. aureus 10% 11% 9%
% other organismsb 20% 53% 29%
% VA 20/40 52% 53% 44%
aIncludes S. epidermidis species.
bIncludes Streptococcus and gram (-) species.Clinical Ophthalmology 2010:4
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